Prostate cancer (PCa) has been associated with endoplasmic reticulum stress (ERS) which activates the inositol requiring protein 1α- X-box binding protein-1 (IREα-XBP-1) pathway. The aim of the study was to investigate the role of this pathway in three human PCa cell lines (LNCaP, PC-3, and DU-145) by evaluating the expression of XBP-1 and glucose-regulated protein 78 (GRP78) genes. The effect of two ERS inducers (Thapsigargin, Tg and tunicamycin, Tm) alone and in combination with an inhibitor of the IRE1α RNase inhibitor (STF-083010) on expression profiling was followed using Quantitative-PCR. In vitro treatment of PCa cells with ERS inducers upregulated expression of XBP-1 gene. STF-083010 inhibited IRE1α-induced splicing of the gene and increased cytotoxicity. Inhibition of IRE1α RNase activity significantly decreased expression of chaperon protein GRP78. The results confirm and extend the concept that selective targeting of IRE1α-XBP-1 pathway might be a novel therapeutic approach that curbs PCa cell progression.
Prostate cancer (PCa) is one of the most common non-cutaneous tumors and the third leading cause of cancer death among males after lung and colorectal cancers world-wide 1. The current therapeutic strategies; anti-androgen therapies, radical prostatectomy as well as radiotherapy/brachytherapy have alleviated symptoms and improved survival but the outcomes and patient compliance have not improved significantly over the last decade 2. Thus, finding novel prognostic tools and new treatment options for therapy-resistant PCa has been not only highly desirable, but also a critical challenge.
Previous research has revealed that both ERS and the unfolded protein response (UPR) activation are implicated in tumorigenesis 3, 4. UPR involves three main signaling pathways: protein kinase RNA-like ER kinase (PERK), inositol requiring kinase1α (IRE1α), and activating transcription factor 6 (ATF6) 3, 4. Under normal conditions, the luminal domain of each of the three integral proteins is kept in an inactive state through the association with a well-known ER chaperone, called binding immunoglobulin protein (BiP; also known as GRP78). GRP78 is one major chaperone system in the ERS recovery and is also considered to be a master regulator of the UPR 5, since it leads to activation of the three sensors. Activated IRE1α sensor is responsible for the non-conventional splicing of unspliced XBP-1 (XBP-1u) mRNA to the active form spliced XBP1 (XBP-1s) through its endoribonuclase activity 6. XBP-1s enters the nucleus and induces transcription of genes correlated with protein-folding capacity and R-associated degradation. XBP-1s is a central UPR effector and previous studies indicates that up- regulation of XBP-1s promotes cell proliferation and invasion of cancerous cells 7, 8.
Manipulation of the key branches of the UPR has been suggested as potential anticancer therapies 7, 9, 10, 11. Due to lack of biochemical and structural understanding of ERS sensors’ interaction with GRP78 the exact role of this chaperon in regulating their activity and in metastasis remains largely unknown 12. However, it is believed that it induces a signaling cascade to mediate tumorigenesis and is linked with increased risk of various types of cancers and with lower survival rate 13. Here, we have investigated the role of IREα-XBP-1 signaling pathway in PCa cell lines (PC3, DU145 and LNCaP) by evaluating the expression of XBP-1 and GRP78 genes using Quantitative PCR.
Human PCa cell lines (DU145, PC3 and LNCaP) were purchased from the American Type Culture Collection (ATCC, Manassas, VA, USA). The cells were recovered in Dulbecco's Modified Eagle Medium/ Nutrient Mixture F-12 (DMEM/F12, Euro Clone, Italy) supplemented with 15% heat inactivated fetal bovine serum (FBS), 100 units/ml of penicillin, 100 μg/ml of streptomycin and 1% amphotericin B (25µg/ml, Caisson). The cells were incubated in a humidified atmosphere of 5% CO2 at 37°C.
2.2. MTT AssaysThe PCa cells were plated at a density of 1 × 104 in 200μl of the culture medium in a 96-well plate and left overnight to adhere. They were cultured for 72h in normal medium and then either left in untreated medium (as control) or medium containing the ERS inducers; thapsigargin (Tg, Santa Cruse, USA) 0.1µM, 0.3µM, 0.5µM, and 1µM or tunicamycin (Tm, Santa Cruse) 1µM, 4µM, 5µM, and 10µm. The plates were read with EPOCH™ Spectrophotometer system (Biotek Instruments, VT, USA) at 590nm absorbance with reference at 630nm. Percentage survival values as compared to the untreated control values against drug concentration were plotted and the approximate 50% inhibitory concentration (IC50) with each PCa cell line was established.
2.3. Evaluation of the IRE1α-XBP-1 PathwayThe dose-gene expression response experiments were initiated when cells reached near-confluence state. Based on data obtained from cytotoxicity, survival and pilot experiments, cells were exposed to 0.3μM Tg or 5μM Tm, individually or in combination with of one of the three following concentrations of the IRE1α RNase inhibitor (STF-083010); 30μM, 60μM or 90μM for various time periods of stimulation: 0, 0.5h, 2h, 3h, 6h, 9h or 24h. DMSO served as a solvent control in all experiments.
2.4. RNA Isolation and Reverse-transcriptionExtraction of total RNA from cells cultured at different conditions was performed using ReliaPrepTM RNA Cell Miniprep System (Promega, Madison, WI, USA). Total RNA concentration was measured by EPOCH™ Spectrophotometer system (Biotek). The RNA was reverse transcribed with a PrimeScriptTM RT Reagent Kit (Takara, Japan). The produced cDNA was diluted with nuclease free water (NFW) to get 10 ng for each sample.
2.5. Quantitative PCRAmplification and quantification of cDNA were performed by KAPA SYBR® Fast Universal qPCR Kit (Kapa, Korea). Primers were designed to differentiate between XBP-1 s and XBP-1u, the following PCR primers were used: XBP-1s (forward 5’TGCTGAGTCCGCAGCAGGT’3 and reverse 5’GCTGGCAGGCTCTGGGGAA’3) and XBP-1u (forward 5’TGCTGAGTCCGCAGCACTC’3 and reverse 5’GCTGGCAGGCTCTGGGGAA’3). The specific primers used for GRP78 were as follows: (forward 5’CGTCCTATGTCGCCTTCACT ’3 and reverse 5’AATGTCTTTGTTTGCCCACC’3). Human GAPDH (housekeeping gene) primers (forward 5’GGAAACTGTGGCGTGATGG’3 and reverse 5’GTCCACCACTGACACGTTG’3). Quantitative PCR was carried out in triplicate, first at 95°C for 3 min, 40 cycles of 95°C for 3 sec, annealing/extension at 60°C for 40 sec using by iQ5 (Biorade™ ) Real-Time detection system. Gene expression levels were normalized to GAPDH, calculated using comparative Ct (2-∆∆CT) analyzing methods of relative quantification.
2.6. Statistical AnalysisAll statistical analyses were performed using SPSS Version 21. Data are expressed as means with standard deviations (SD). ANOVA was used to compare the experimental groups with the control. A P ≤ 0.05 vale was considered statistically significant.
To estimate cell viability in vitro, the MTT assay was used to assess the inhibitory effect of Tm and Tg on human PCa cells. When compared to DMSO-treated and untreated controls cells, the 72h-treatment of both drugs resulted in concentration-dependent and statistically significant (p≤ 0.05) reductions in cell survival in all types of PCa cells. In addition, Tm and Tg differentially inhibited the growth of PCa cells; the DU145 cells showed the highest tolerance to Tg, while PC3 cells were the most sensitive. In contrast, LNCaP cells were the most Tm-resistant and DU145 the most sensitive to this drug. On the bases of cytotoxicity and cell survival data, 0.3μM and 5μM of Tg and Tm, respectively, which left about 50% of cells alive, were chosen for further experiments.
3.2. Expression of XBP-1Expression of XBP-1s and XBP-1u was characterized in the three PCa cell lines by quantitative PCR analysis. The results showed upregulation of XBP-1s after treatment of the three PCa cells with Tg at 0.3µM or with Tm at 5µM at different intervals (Figure 1). Compared with the control, DU145 cells were the fastest (after 2h) and LNCaP cells the slowest (after 9h) to express XBP-1s mRNA; 2h and 9h, respectively. In PC3 cells, the highest level of XBP-1s gene was recorded at 6h and at 2h with Tg and Tm, respectively. All the three cell lines exhibited disparity in the expression level of XBP-1s; highest level of expression seen in DU145, while the lowest levels observed in PC3 cells. The XBP-1u expression was significantly lower than the spliced isoform and showed no specific pattern of expression in different cell lines. Maximum levels of expression of this isoform were noted in Tm-exposed LNCaP cells.
3.3. STF-083010 Inhibits the IRE1α- XBP-1 PathwayFigure 2 depicts inhibition of IRE1α- XBP-1 pathway by STF-083010. The PCa cells co-treated with an ERS inducer (Tm or Tg) and an IRE1α suppressor (STF-083010) responded to these conditions by downregulation of XBP-1s to varying degrees depending on cell type and concentration of STF-083010. Relative to the control, STF-083010 greatly attenuated XBP-1s, even after Tm or Tg treatment in all PCa cells. PC3 cells were the most sensitive to STF-083010 inhibition. XBP-1expression DU145 was affected to a lesser extent by concurrent treatment with Tm and STF-083010 than with Tg and STF-083010. Conversely, LNCaP cells showed a reverse pattern; they were more resistant to STF-083010-Tg effect than to STF-083010- Tm.
To test if XBP-1 was responsible for induction of GRP78, the levels of GRP78 expression were examined in ERS- exposed PCa cells before (Figure 3) and after (Figure 4) inhibition of IRE1α-XBP-1 pathway using STF-083010. The results confirmed that GRP78 expression was downregulated following co-treatment of cells either with Tm or Tg and STF-083010.
XBP-1 is a transcription factor that activates chaperone proteins to enhance protein folding and degradation of misfolded proteins. Several researchers reported that overexpression of active form of XBP-1, XBP1-s, correlates with angiogenesis in colorectal and pancreatic cancers 14, enhances breast cancer progression 7, 15, promotes pathogenesis of multiple myeloma 16, colorectal adenoma 8, melanoma 17 and glioma 18. In contrast, in other previous finding 19. XBP-1was down regulated in PCa in vivo and in vitro. The divergence in the results of XBP-1 expression may be partly related to cell type as well as to potentials for accommodation with oxygen and nutrients shortages through various tumor tissues.
Previous studies indicated that tumor invasion is regulated by ATF6 20, PERK 21, and IRE1α 18, 22, 23 pathways of the UPR. The signaling pathway by which sensors of UPR regulates apoptosis is not completely understood. Modulation of IRE1α-XBP-1 signaling pathway with small molecules such as STF-083010 has been demonstrated as a promising way for cancer therapy 14. Recently, blocked XBP-1s in glioma cells demonstrated a decreased ability of tumor formation 23. Furthermore, several research groups reported that inhibition of XBP-1 expression enhances impairment tumor progression 8, 16, 18. Our results showed that STF-083010 greatly attenuated the XBP-1s expression in PCa cells, even after Tm or Tg treatment. One of the most important chaperone proteins in UPR is GRP78 and there are several reports which correlate between upregulation of GRP78 and protection of PCa 24, 25 and other cancer cells 13, 20, 23, 26, 27, 28 from apoptosis. Moreover, different PCa cells exhibited different behavior in gene expression depending on the features of the cell line. It is known that LNCaP cells are androgen-sensitive, while DU145 and PC3 are not 29, 30, which makes the latter type cells more aggressive and have a higher metastatic potential than LNCaP.
This study is the first to show the correlation between expression of XBP-1 and GRP78 genes in PCa cells. Co-treatment of PCa cells with an ERS inducer and an IRE1α suppressor (STF-083010) suppressed gene activity. Therefore, inhibition of IRE1α-XBP-1 pathway may be considered a useful approach for cancer chemotherapeutic.
ATF6, activating transcription factor 6; DMEM/F12, Dulbecco's Modified Eagle Medium/ Nutrient Mixture F-12; ER, endoplasmic reticulum; ERS, endoplasmic reticulum stress; FBS, fetal bovine serum; GRP78, glucose-regulated protein 78; IREα, inositol requiring protein 1α; NFW, nuclease free water; PCa, prostate cancer; PERK; protein kinase RNA-like ER kinase; Tg, thapsigargin; Tm, tunicamycin; XBP-1, UPR, unfolded protein response; X-Box Binding Protein-1; XBP-1s, spliced XBP-1; XBP-1u, unspliced XBP-1
This work was supported by research grant number (28/2015) to the first author from the Deanship of Scientific Research and Graduate Studies at Yarmouk University.
The authors have no competing interests.
| [1] | Siegel, R.L., Miller, K.D., Jemal, A, “Cancer statistics”, CA Cancer Journal for Clinicians, 68.7-30. 2018. | ||
| In article | |||
| [2] | Litwin, M.S., Tan, H.J, “The diagnosis and treatment of prostate cancer: A review”, JAMA, 317. 2532-2542. 2017. | ||
| In article | View Article PubMed | ||
| [3] | Corazzari, M., Gagliardi, M., Fimia, G.M., Piacentini, M, “Endoplasmic reticulum stress, unfolded protein response, and cancer cell fate”, Frontiers in Oncology, 7.78. 2017. | ||
| In article | |||
| [4] | Doultsinos, D., Avril, T., Lhomond, S., Dejeans, N., Guédat, P., Chevet, E, “Control of the unfolded protein response in health and disease. SLAS DISCOVERY”, Advancing Life Sciences R&D, 22 (7).787-800. 2017. | ||
| In article | |||
| [5] | Pincus, D., Chevalier, M.W., Aragon, T., van Anken, E., Vidal, S.E., El-Samad, H, “BiP binding to the ER-stress sensor Ire1 tunes the homeostatic behavior of the unfolded protein response”, PLoS Biology, 8 (7). e1000415. 2010. | ||
| In article | View Article PubMed | ||
| [6] | Moore, K., Hollien, J, “Ire1-mediated decay in mammalian cells relies on mRNA sequence, structure, and translational status”, Molecular Biology of the Cell, 26(16).2873-2884. 2015. | ||
| In article | |||
| [7] | Davies, M.P., Barraclough, D.L., Stewart, C., Joyce, K.A., Eccles, R.M., Barraclough, R., Rudland, P.S., Sibson, D.R, “Expression and splicing of unfolded protein response gene XBP-1 are significantly associated with clinical outcome of endocrine-treated breast cancer”, International Journal of Cancer, 123. 85-88. 2008. | ||
| In article | View Article PubMed | ||
| [8] | Mhaidat, N.M., Alzoubi, K.H., Abushbak, A, “X-box binding protein 1 (XBP-1) enhances colorectal cancer cell invasion”, Journal of chemotherapy, 27 (3). 167-173. 2015. | ||
| In article | View Article PubMed | ||
| [9] | Guha, P., Kaptan, E., Gade, P., Kalvakolanu, D.V., Ahmed, H, “Tunicamycin induced endoplasmic reticulum stress promotes apoptosis of prostate cancer cells by activating mTORC1”, Oncotarget, 8 (40). 68191-68207. 2017. | ||
| In article | View Article PubMed | ||
| [10] | Sheng, X., Arnoldussen, Y.J., Storm, M., Tesikova, M., Nenseth, H.Z., Zhao, S., Fazli, L., Rennie, P., Risberg, B., Wæhre, H., Danielsen, H., Mills, I.G., Jin, Y., Hotamisligil, G., Saatcioglu, F, “Divergent androgen regulation of unfolded protein response pathways drives prostate cancer”, EMBO Molecular Medicine, 7. 788-801. 2015. | ||
| In article | View Article PubMed | ||
| [11] | Storm, M., Sheng, X., Arnoldussen, Y.J., Saatcioglu, F, “Prostate cancer and the unfolded protein response”, Oncotarget, 7. 54051-54066. 2016. | ||
| In article | View Article PubMed | ||
| [12] | Wang, C., Cai, L., Liu, J., Wang, G., Li, H., Wang, X., Xu, W., Ren, M., Feng, L., Liu, P., Zhang, C, “MicroRNA-30a-5p inhibits the growth of renal cell carcinoma by modulating GRP78 expression”, Cellular Physiology and Biochemistry, 43. 2405-2419. 2017. | ||
| In article | View Article PubMed | ||
| [13] | Niu, Z., Wang, M., Zhou, L., Yao, L., Liao, Q., Zhao, Y, “Elevated GRP78 expression is associated with poor prognosis in patients with pancreatic cancer”, Scientific Reports, 5. 16067. 2015. | ||
| In article | View Article PubMed | ||
| [14] | Romero-Ramirez, L., Cao, H., Regalado, M.P., Kambham, N., Siemann, D., Kim, J.J., Le, Q.T., Koong, A.C, “X box-binding protein 1 regulates angiogenesis in human pancreatic adenocarcinomas”, Translational Oncology, 2. 31-38. 2009. | ||
| In article | View Article PubMed | ||
| [15] | Ming, J., Ruan, S., Wang, M., Ye, D., Fan, N., Meng, Q., Tian, B., Huang, T, “A novel chemical, STF-083010, reverses tamoxifen-related drug resistance in breast cancer by inhibiting IRE1/XBP1”, Oncotarget, 6(38). 40692-40703. 2015. | ||
| In article | View Article PubMed | ||
| [16] | Mimura, N., Fulciniti, M., Gorgun, G., Tai, Y.T., Cirstea, D., Santo, L., Hu, Y., Fabre, C., Minami, J., Ohguchi, H., Kiziltepe, T., Ikeda, H., Kawano, Y., French, M., Blumenthal, M., Tam, V., Kertesz, N.L., Malyankar, U.M., Hokenson, M., Pham, T., Zeng, Q., Patterson, J.B., Richardson, P.G., Munshi, N.C., Anderson, K.C, “Blockade of XBP1 splicing by inhibition of IRE1alpha promising therapeutic option in multiple myeloma”, Blood, 119. 5772-5781. 2012. | ||
| In article | View Article PubMed | ||
| [17] | Chen, C., Zhang, X, “IRE1α XBP1 pathway promotes melanoma progression by regulating IL 6/STAT3 signaling”, Journal of Translational Medicine, 15. 42. 2017. | ||
| In article | View Article PubMed | ||
| [18] | Auf, G., Jabouille, A., Guérit, S., Pineau, R., Delugin, M., Bouchecareilh, M, Magnin, N., Favereaux, A., Maitre, M., Gaiser, T., von Deimling, A., Czabanka, M., Vajkoczy, P., Chevet, E., Bikfalvi, A., Moenner, M, “Inositol-requiring enzyme 1α is a key regulator of angiogenesis and invasion in malignant glioma”, Proceedings of the National Academy of Sciences, 107(35). 15553-15558. 2010. | ||
| In article | View Article PubMed | ||
| [19] | Alghadi, A.Y., Khalil, A.M., Alazab, R.S., Aldaoud, N.H., Zyoud, A. M-S,” Unique expression of the XBP1 gene correlates with human prostate cancer”, Journal of Investigative Genomics, 4(2). 00091. 2017. | ||
| In article | |||
| [20] | Lin, Y.H., Friederichs, J., Black, M.A., Mages, J., Rosenberg, R., Guilford, P.J., Phillips, V., Thompson-Fawcett, M., Kasabov, N., Toro, T., Merrie, A.E., van Rij, A., Yoon, H.S., McCall, J.L., Siewert, J.R., Holzmann, B., Reeve, A.E, “ Multiple gene expression classifiers from different array platforms predict poor prognosis of colorectal cancer”, Clinical cancer research: an official journal of the American Association for Cancer Research, 13(2). 498-507. 2007. | ||
| In article | |||
| [21] | Feng, Y.X., Jin, D.X., Solcol, E.S., Reinhardt, F., Miller, D.H., Gupta, P.B, “Cancer-specific PERK signaling drives invasion and metastasis through CREB3L1”, Nature Communications, 2017. | ||
| In article | View Article | ||
| [22] | Sun, H., Lin, D-C., Guo, X., Masouleh, B.k., Gery, S., Cao, Q., Alkan, S., Ikezoe, T., Akiba, C., Paquette, R., Chien, W., Müller-Tidow, C., Jing, Y., Agelopoulos, K., Müschen, M., Koeffler, H.P, “Inhibition of IRE1α-driven pro-survival pathways is a promising therapeutic application in acute myeloid leukemia”, Oncotarget, 7 (14). 18736-18749. 2016. | ||
| In article | View Article PubMed | ||
| [23] | Liu, Y., Hou, X., Liu, M., Yang, Z., Bi, Y., Zou, H., Wu, J., Che, H., Li, C., Wang, X., Wang, K., Zhong, C., Zhang, J., Yu, T., Bian, Q., Chai, S., Liu, H., Ai, J., Zhao, S, “XBP1 silencing decreases glioma cell viability and glycolysis possibly by inhibiting HK2 expression”, The Journal of Neuro-Oncology, 126(3). 455-462. 2016. | ||
| In article | View Article PubMed | ||
| [24] | Pootrakul, L., Datar, R.H., Shi, S-R., Cai, J., Hawes, D., Groshen, S.G., Lee, A.S., Cote, R.J, “Expression of stress response protein Grp78 is associated with the development of castration-resistant prostate cancer”, Clinical Cancer Research, 12.5987-5993. 2006. | ||
| In article | |||
| [25] | Daneshmand, S., Quek, M.L., Lin, E., Lee, C., Cote, R.J., Hawes, D., Cai, J., Groshen, S., Lieskovsky, G., Skinner, D.G., Lee, A.S., Pinski, J, “Glucose-regulated protein GRP78 is up-regulated in prostate cancer and correlates with recurrence and survival”, Human Pathology, 38.1547-1552. 2007. | ||
| In article | |||
| [26] | Xing, X., Li, Y., Liu, H., Wang, L., Sun, L,” Glucose regulated protein 78 (GRP78) is overexpressed in colorectal carcinoma and regulates colorectal carcinoma cell growth and apoptosis”, Acta Histochemica, 113. 777-782. 2011; | ||
| In article | View Article PubMed | ||
| [27] | Lee, H.K., Xiang, C., Cazacu, S., Finniss, S., Kazimirsky, G., Lemke, N., Lehman, N.L., Rempe, S.A., Mikkelsen, T., Brodieet, C, “GRP78 is overexpressed in glioblastomas and regulates glioma cell growth and apoptosis”, Neuro-Oncology, 10. 236-43. 2008. | ||
| In article | View Article PubMed | ||
| [28] | Fu, R., Yang, P., Wu, H.L., Li, Z.W., Li, Z.Y, “GRP78 secreted by colon cancer cells facilitates cell proliferation via PI3K/Akt signaling”, Asian Pacific Journal of Cancer Prevention, 15.7245–7249. 2014. | ||
| In article | |||
| [29] | Schmidt, B.M., Erdman Jr, J.W., Lila, M.A, “Differential effects of blueberry proanthocyanidins on androgen sensitive and insensitive human prostate cancer cell lines”, Cancer Letters, 231(2). 240-246. 2006. | ||
| In article | View Article PubMed | ||
| [30] | Kim, K.Y., Seo, Y.K., Yu, S.N., Kim, S.H., Suh, P.G., Ji, J-H., Yu, H-S., Park, Y-M., Ahn, S-C, “Gene expression profiling from a prostate cancer PC-3 cell line treated with salinomycin predicts cell cycle arrest and endoplasmic reticulum stress”, Journal of Cancer Science and Therapy, 5. 023-030. 2012. | ||
| In article | |||
Published with license by Science and Education Publishing, Copyright © 2018 Ahmad M. Khalil, Ahmad Y. Alghadi, Rahaf M. T. Shahen, Jehad W. Elasad and Khaleel I. Jawasreh
This work is licensed under a Creative Commons Attribution 4.0 International License. To view a copy of this license, visit
https://creativecommons.org/licenses/by/4.0/
| [1] | Siegel, R.L., Miller, K.D., Jemal, A, “Cancer statistics”, CA Cancer Journal for Clinicians, 68.7-30. 2018. | ||
| In article | |||
| [2] | Litwin, M.S., Tan, H.J, “The diagnosis and treatment of prostate cancer: A review”, JAMA, 317. 2532-2542. 2017. | ||
| In article | View Article PubMed | ||
| [3] | Corazzari, M., Gagliardi, M., Fimia, G.M., Piacentini, M, “Endoplasmic reticulum stress, unfolded protein response, and cancer cell fate”, Frontiers in Oncology, 7.78. 2017. | ||
| In article | |||
| [4] | Doultsinos, D., Avril, T., Lhomond, S., Dejeans, N., Guédat, P., Chevet, E, “Control of the unfolded protein response in health and disease. SLAS DISCOVERY”, Advancing Life Sciences R&D, 22 (7).787-800. 2017. | ||
| In article | |||
| [5] | Pincus, D., Chevalier, M.W., Aragon, T., van Anken, E., Vidal, S.E., El-Samad, H, “BiP binding to the ER-stress sensor Ire1 tunes the homeostatic behavior of the unfolded protein response”, PLoS Biology, 8 (7). e1000415. 2010. | ||
| In article | View Article PubMed | ||
| [6] | Moore, K., Hollien, J, “Ire1-mediated decay in mammalian cells relies on mRNA sequence, structure, and translational status”, Molecular Biology of the Cell, 26(16).2873-2884. 2015. | ||
| In article | |||
| [7] | Davies, M.P., Barraclough, D.L., Stewart, C., Joyce, K.A., Eccles, R.M., Barraclough, R., Rudland, P.S., Sibson, D.R, “Expression and splicing of unfolded protein response gene XBP-1 are significantly associated with clinical outcome of endocrine-treated breast cancer”, International Journal of Cancer, 123. 85-88. 2008. | ||
| In article | View Article PubMed | ||
| [8] | Mhaidat, N.M., Alzoubi, K.H., Abushbak, A, “X-box binding protein 1 (XBP-1) enhances colorectal cancer cell invasion”, Journal of chemotherapy, 27 (3). 167-173. 2015. | ||
| In article | View Article PubMed | ||
| [9] | Guha, P., Kaptan, E., Gade, P., Kalvakolanu, D.V., Ahmed, H, “Tunicamycin induced endoplasmic reticulum stress promotes apoptosis of prostate cancer cells by activating mTORC1”, Oncotarget, 8 (40). 68191-68207. 2017. | ||
| In article | View Article PubMed | ||
| [10] | Sheng, X., Arnoldussen, Y.J., Storm, M., Tesikova, M., Nenseth, H.Z., Zhao, S., Fazli, L., Rennie, P., Risberg, B., Wæhre, H., Danielsen, H., Mills, I.G., Jin, Y., Hotamisligil, G., Saatcioglu, F, “Divergent androgen regulation of unfolded protein response pathways drives prostate cancer”, EMBO Molecular Medicine, 7. 788-801. 2015. | ||
| In article | View Article PubMed | ||
| [11] | Storm, M., Sheng, X., Arnoldussen, Y.J., Saatcioglu, F, “Prostate cancer and the unfolded protein response”, Oncotarget, 7. 54051-54066. 2016. | ||
| In article | View Article PubMed | ||
| [12] | Wang, C., Cai, L., Liu, J., Wang, G., Li, H., Wang, X., Xu, W., Ren, M., Feng, L., Liu, P., Zhang, C, “MicroRNA-30a-5p inhibits the growth of renal cell carcinoma by modulating GRP78 expression”, Cellular Physiology and Biochemistry, 43. 2405-2419. 2017. | ||
| In article | View Article PubMed | ||
| [13] | Niu, Z., Wang, M., Zhou, L., Yao, L., Liao, Q., Zhao, Y, “Elevated GRP78 expression is associated with poor prognosis in patients with pancreatic cancer”, Scientific Reports, 5. 16067. 2015. | ||
| In article | View Article PubMed | ||
| [14] | Romero-Ramirez, L., Cao, H., Regalado, M.P., Kambham, N., Siemann, D., Kim, J.J., Le, Q.T., Koong, A.C, “X box-binding protein 1 regulates angiogenesis in human pancreatic adenocarcinomas”, Translational Oncology, 2. 31-38. 2009. | ||
| In article | View Article PubMed | ||
| [15] | Ming, J., Ruan, S., Wang, M., Ye, D., Fan, N., Meng, Q., Tian, B., Huang, T, “A novel chemical, STF-083010, reverses tamoxifen-related drug resistance in breast cancer by inhibiting IRE1/XBP1”, Oncotarget, 6(38). 40692-40703. 2015. | ||
| In article | View Article PubMed | ||
| [16] | Mimura, N., Fulciniti, M., Gorgun, G., Tai, Y.T., Cirstea, D., Santo, L., Hu, Y., Fabre, C., Minami, J., Ohguchi, H., Kiziltepe, T., Ikeda, H., Kawano, Y., French, M., Blumenthal, M., Tam, V., Kertesz, N.L., Malyankar, U.M., Hokenson, M., Pham, T., Zeng, Q., Patterson, J.B., Richardson, P.G., Munshi, N.C., Anderson, K.C, “Blockade of XBP1 splicing by inhibition of IRE1alpha promising therapeutic option in multiple myeloma”, Blood, 119. 5772-5781. 2012. | ||
| In article | View Article PubMed | ||
| [17] | Chen, C., Zhang, X, “IRE1α XBP1 pathway promotes melanoma progression by regulating IL 6/STAT3 signaling”, Journal of Translational Medicine, 15. 42. 2017. | ||
| In article | View Article PubMed | ||
| [18] | Auf, G., Jabouille, A., Guérit, S., Pineau, R., Delugin, M., Bouchecareilh, M, Magnin, N., Favereaux, A., Maitre, M., Gaiser, T., von Deimling, A., Czabanka, M., Vajkoczy, P., Chevet, E., Bikfalvi, A., Moenner, M, “Inositol-requiring enzyme 1α is a key regulator of angiogenesis and invasion in malignant glioma”, Proceedings of the National Academy of Sciences, 107(35). 15553-15558. 2010. | ||
| In article | View Article PubMed | ||
| [19] | Alghadi, A.Y., Khalil, A.M., Alazab, R.S., Aldaoud, N.H., Zyoud, A. M-S,” Unique expression of the XBP1 gene correlates with human prostate cancer”, Journal of Investigative Genomics, 4(2). 00091. 2017. | ||
| In article | |||
| [20] | Lin, Y.H., Friederichs, J., Black, M.A., Mages, J., Rosenberg, R., Guilford, P.J., Phillips, V., Thompson-Fawcett, M., Kasabov, N., Toro, T., Merrie, A.E., van Rij, A., Yoon, H.S., McCall, J.L., Siewert, J.R., Holzmann, B., Reeve, A.E, “ Multiple gene expression classifiers from different array platforms predict poor prognosis of colorectal cancer”, Clinical cancer research: an official journal of the American Association for Cancer Research, 13(2). 498-507. 2007. | ||
| In article | |||
| [21] | Feng, Y.X., Jin, D.X., Solcol, E.S., Reinhardt, F., Miller, D.H., Gupta, P.B, “Cancer-specific PERK signaling drives invasion and metastasis through CREB3L1”, Nature Communications, 2017. | ||
| In article | View Article | ||
| [22] | Sun, H., Lin, D-C., Guo, X., Masouleh, B.k., Gery, S., Cao, Q., Alkan, S., Ikezoe, T., Akiba, C., Paquette, R., Chien, W., Müller-Tidow, C., Jing, Y., Agelopoulos, K., Müschen, M., Koeffler, H.P, “Inhibition of IRE1α-driven pro-survival pathways is a promising therapeutic application in acute myeloid leukemia”, Oncotarget, 7 (14). 18736-18749. 2016. | ||
| In article | View Article PubMed | ||
| [23] | Liu, Y., Hou, X., Liu, M., Yang, Z., Bi, Y., Zou, H., Wu, J., Che, H., Li, C., Wang, X., Wang, K., Zhong, C., Zhang, J., Yu, T., Bian, Q., Chai, S., Liu, H., Ai, J., Zhao, S, “XBP1 silencing decreases glioma cell viability and glycolysis possibly by inhibiting HK2 expression”, The Journal of Neuro-Oncology, 126(3). 455-462. 2016. | ||
| In article | View Article PubMed | ||
| [24] | Pootrakul, L., Datar, R.H., Shi, S-R., Cai, J., Hawes, D., Groshen, S.G., Lee, A.S., Cote, R.J, “Expression of stress response protein Grp78 is associated with the development of castration-resistant prostate cancer”, Clinical Cancer Research, 12.5987-5993. 2006. | ||
| In article | |||
| [25] | Daneshmand, S., Quek, M.L., Lin, E., Lee, C., Cote, R.J., Hawes, D., Cai, J., Groshen, S., Lieskovsky, G., Skinner, D.G., Lee, A.S., Pinski, J, “Glucose-regulated protein GRP78 is up-regulated in prostate cancer and correlates with recurrence and survival”, Human Pathology, 38.1547-1552. 2007. | ||
| In article | |||
| [26] | Xing, X., Li, Y., Liu, H., Wang, L., Sun, L,” Glucose regulated protein 78 (GRP78) is overexpressed in colorectal carcinoma and regulates colorectal carcinoma cell growth and apoptosis”, Acta Histochemica, 113. 777-782. 2011; | ||
| In article | View Article PubMed | ||
| [27] | Lee, H.K., Xiang, C., Cazacu, S., Finniss, S., Kazimirsky, G., Lemke, N., Lehman, N.L., Rempe, S.A., Mikkelsen, T., Brodieet, C, “GRP78 is overexpressed in glioblastomas and regulates glioma cell growth and apoptosis”, Neuro-Oncology, 10. 236-43. 2008. | ||
| In article | View Article PubMed | ||
| [28] | Fu, R., Yang, P., Wu, H.L., Li, Z.W., Li, Z.Y, “GRP78 secreted by colon cancer cells facilitates cell proliferation via PI3K/Akt signaling”, Asian Pacific Journal of Cancer Prevention, 15.7245–7249. 2014. | ||
| In article | |||
| [29] | Schmidt, B.M., Erdman Jr, J.W., Lila, M.A, “Differential effects of blueberry proanthocyanidins on androgen sensitive and insensitive human prostate cancer cell lines”, Cancer Letters, 231(2). 240-246. 2006. | ||
| In article | View Article PubMed | ||
| [30] | Kim, K.Y., Seo, Y.K., Yu, S.N., Kim, S.H., Suh, P.G., Ji, J-H., Yu, H-S., Park, Y-M., Ahn, S-C, “Gene expression profiling from a prostate cancer PC-3 cell line treated with salinomycin predicts cell cycle arrest and endoplasmic reticulum stress”, Journal of Cancer Science and Therapy, 5. 023-030. 2012. | ||
| In article | |||